Literature DB >> 10632461

Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance.

J J Wyman1, A M Hornstein, P A Meitner, S Mak, P Verdier, J A Block, J Pan, R M Terek.   

Abstract

We report on two chondrosarcoma cell lines, FS and AQ, that may be used as models of multidrug resistance in chondrosarcoma. Multidrug resistance-1 expression was assayed with reverse transcription-polymerase chain reaction. Immunostaining for the multidrug resistance-1 product, P-glycoprotein, was performed with the monoclonal antibody C494. Intracellular levels of doxorubicin were measured by fluorescent emission at 590 nm after 1 hour of incubation with the agent and again after 1, 2, and 4-hour washout periods. Chemosensitivity was assayed by staining micropellet cultures of AQ and FS cells with fluorescein acetate before and after the cells were exposed to varying doses of doxorubicin for 48 hours. Cytotoxicity was assessed by comparison of computer-processed images before and after treatment. The FS cell line was positive for multidrug resistance-1 expression, stained heavily for P-glycoprotein, and had significantly lower intracellular levels of doxorubicin than the AQ cell line, which was negative for multidrug resistance-1 and P-glycoprotein. Chemosensitivity testing showed that the FS cell line was significantly more resistant to doxorubicin than was the AQ cell line at all doses tested. Our results show that multidrug resistance-1 expression in a human chondrosarcoma cell line results in resistance to doxorubicin in vitro.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632461     DOI: 10.1002/jor.1100170619

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  22 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 2.  Multidisciplinary management of primary tumors of the vertebral column.

Authors:  Wesley Hsu; Thomas A Kosztowski; Hasan A Zaidi; Michael Dorsi; Ziya L Gokaslan; Jean-Paul Wolinsky
Journal:  Curr Treat Options Oncol       Date:  2009-06-23

Review 3.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

4.  Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS-2/8 Chondrosarcoma Cells.

Authors:  William P Shield; Ashley Cellini; Hongying Tian; Kim Wilson; Yang Dan; Joshua M Abzug; Sonia Garcia; Norifumi Moritani; Ivan Alferiev; Michael Chorny; Masaharu Takigawa; Vincent Y Ng; Masahiro Iwamoto; Motomi Enomoto-Iwamoto
Journal:  J Orthop Res       Date:  2019-12-19       Impact factor: 3.494

5.  Treatment of Bone Tumors.

Authors:  Rajiv Rajani; C Parker Gibbs
Journal:  Surg Pathol Clin       Date:  2012-03

6.  siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.

Authors:  Dae Won Kim; Kyung-Ok Kim; Mike J Shin; Jung Hee Ha; Sung Wook Seo; Jay Yang; Francis Y Lee
Journal:  Mol Cancer       Date:  2009-05-15       Impact factor: 27.401

7.  Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

Authors:  Yvonne de Jong; Annemiek M van Maldegem; Adrian Marino-Enriquez; Danielle de Jong; Johnny Suijker; Inge H Briaire-de Bruijn; Alwine B Kruisselbrink; Anne-Marie Cleton-Jansen; Karoly Szuhai; Hans Gelderblom; Jonathan A Fletcher; Judith V M G Bovée
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

8.  Estimated cause-specific survival continues to improve over time in patients with chondrosarcoma.

Authors:  Kyle R Duchman; Charles F Lynch; Joseph A Buckwalter; Benjamin J Miller
Journal:  Clin Orthop Relat Res       Date:  2014-04-05       Impact factor: 4.176

Review 9.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

10.  Prognostic Factors and a Nomogram Predicting Overall Survival in Patients with Limb Chondrosarcomas: A Population-Based Study.

Authors:  Xinjie Wu; Yanlei Wang; Wei Sun; Mingsheng Tan
Journal:  Biomed Res Int       Date:  2021-05-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.